RT Journal Article SR Electronic T1 Single versus multiple antenatal steriods in threatened preterm delivery? JF Archives of Disease in Childhood - Fetal and Neonatal Edition JO Arch Dis Child Fetal Neonatal Ed FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health DO 10.1136/adc.2008.137935 A1 Gusztav BELTEKI A1 Gordon C Smith YR 2008 UL http://fn.bmj.com/content/early/2008/10/06/adc.2008.137935.abstract AB The first demonstration that antenatal maternal glucocorticoid treatment reduced neonatal morbidity was reported by Liggins and colleagues in 1972 (1). In the following two decades antenatal corticosteroid prophylaxis gradually found its way into clinical practice and became an accepted part of the standard care by the early nineties (2,3). It clearly reduces overall neonatal mortality, the risk of respiratory distress syndrome (RDS) and the need for respiratory support (4). It also decreases the risk of other complications of prematurity, including intraventricular haemorrhage (IVH) and necrotizing enterocolitis (NEC), but not bronchopulmonary dysplasia (BPD). The current recommendation is to give two doses of 12 mg betamethasone, 24 hours apart, to women who may deliver within seven days and are less than 35 weeks pregnant (5,6,7). Most benefit is seen when delivery follows the second dose by more than 24 hours; however, even an incomplete course reduces neonatal morbidity and mortality (8).